The Global Tafamidis Meglumine Market was valued at USD 235.8 Million in 2023 and is projected to reach USD 418.6 Million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 10.2% during the forecast period (2024–2029). This growth is being driven by increasing diagnosis rates of transthyretin amyloidosis (ATTR), expanding clinical applications, and the accelerating adoption of targeted therapies for rare cardiac and neurological conditions.

As the pharmaceutical industry continues to innovate treatments for previously underserved patient populations, the spotlight is on the key manufacturers and suppliers who are advancing production capabilities, ensuring quality standards, and expanding global access. In this blog, we profile the Top 10 Companies in the Tafamidis Meglumine Industry—a mix of innovator pharma companies, API manufacturers, and generic producers shaping the future of ATTR amyloidosis treatment.

---

🔟 1. Pfizer Inc.

Headquarters: New York, New York, USA
Key Offering: Tafamidis Meglumine API and Finished Products

Pfizer is the original developer and global marketer of tafamidis meglumine under the brand name Vyndaqel/Vyndamax. The company holds patents for the treatment of both hereditary and wild-type ATTR cardiomyopathy, with extensive clinical trial experience and global regulatory expertise.

Research and Development Initiatives:

• Continuing clinical development for expanded indications

• Global patient support and access programs

• Investment in next-generation TTR stabilizers

Download FREE Sample Report: 2023-2028 Global and Regional Tafamidis Meglumine Industry Status and Prospects Professional Market – View in Detailed Research Report

---

9️⃣ 2. SUANFARMA

Headquarters: Milan, Italy
Key Offering: Tafamidis Meglumine API

SUANFARMA is a leading manufacturer of high-quality active pharmaceutical ingredients, including tafamidis meglumine. The company specializes in the development and production of complex molecules for the pharmaceutical industry with stringent quality controls.

Research and Development Initiatives:

• GMP-compliant manufacturing facilities

• Global distribution network for APIs

---

8️⃣ 3. Nuray Chemicals

Headquarters: Mumbai, India
Key Offering: Tafamidis Meglumine (Purity ≥99% and ≥99.5%)

Nuray Chemicals specializes in the synthesis and supply of pharmaceutical intermediates and APIs, including tafamidis meglumine in various purity grades to meet diverse manufacturing requirements.

Research and Development Initiatives:

• Process optimization for cost-effective production

• Custom synthesis capabilities for research purposes

---

7️⃣ 4. Neuland Laboratories

Headquarters: Hyderabad, India
Key Offering: Tafamidis Base and Tafamidis Meglumine

Neuland Laboratories is an established manufacturer of APIs and pharmaceutical intermediates with advanced R&D capabilities in process chemistry and scale-up operations.

Research and Development Initiatives:

• Development of non-infringing synthesis routes

• Regulatory filings support for global markets

---

6️⃣ 5. Cangzhou Enke Pharma

Headquarters: Cangzhou, China
Key Offering: Tafamidis Meglumine in multiple purity specifications

Cangzhou Enke Pharma focuses on the development, production, and sale of pharmaceutical APIs and intermediates, including tafamidis meglumine for both domestic Chinese market and international exports.

Research and Development Initiatives:

• GMP manufacturing for regulated markets

• Strategic partnerships with global pharmaceutical companies

---

5️⃣ 6. Dr. Reddy's Laboratories

Headquarters: Hyderabad, India
Key Offering: Tafamidis Meglumine API and Finished Dosage Forms

Dr. Reddy’s Laboratories has significant expertise in complex API manufacturing and has included tafamidis meglumine in its growing portfolio of specialty pharmaceuticals.

Research and Development Initiatives:

• Development of cost-effective synthesis processes

• Global regulatory strategy development

Download FREE Sample Report: 2023-2028 Global and Regional Tafamidis Meglumine Industry Status and Prospects Professional Market – View in Detailed Research Report

---

4️⃣ 7. Teva Pharmaceutical Industries

Headquarters: Tel Aviv, Israel
Key Offering: Tafamidis Meglumine API and Generic Formulations

Teva is one of the world’s largest generic pharmaceutical companies with extensive manufacturing capabilities and global distribution networks for complex APIs.

Research and Development Initiatives:

• Global supply chain optimization for specialty medicines

• Partnerships with healthcare providers for patient access

---

3️⃣ 8. Mylan N.V. (Now part of Viatris)

Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Generic Tafamidis formulations

Mylan, now operating as part of Viatris, has capabilities in complex generic product development and manufacturing, positioning them for future market entry.

Research and Development Initiatives:

• Complex generic product portfolio expansion

• Focus on improving treatment affordability worldwide

---

2️⃣ 9. Sun Pharmaceutical Industries

Headquarters: Mumbai, India
Key Offering: Tafamidis Meglumine API and Finished Products

Sun Pharma is a global pharmaceutical company with strong capabilities in specialty and complex generic products, including development of tafamidis meglumine formulations.

Research and Development Initiatives:

• Development of alternative salt forms for improved stability

• Strategic acquisitions to strengthen API manufacturing capabilities

---

1️⃣ 10. Cipla Limited

Headquarters: Mumbai, India
Key Offering: Tafamidis Meglumine for pharmaceutical applications

Cipla has established itself as a global pharmaceutical company with focus on affordable medicines and has capabilities in complex API manufacturing.

Research and Development Initiatives:

• Focus on developing markets and emerging economies

• Partnerships for technology transfer and local manufacturing

Get Full Report Here: 2023-2028 Global and Regional Tafamidis Meglumine Industry Status and Prospects Professional Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Tafamidis Meglumine Is More Accessible and Advanced

The tafamidis meglumine market is undergoing significant transformation. While branded products still dominate major markets, the industry is preparing for patent expirations with investments in generic API production, formulation development, and expanded clinical applications.

📈 Key Trends Shaping the Market:

• Increasing diagnostic rates through improved awareness campaigns

• Geographic expansion into emerging markets with growing healthcare infrastructure

• Development of next-generation TTR stabilizers with improved efficacy

• Growing pipeline of combination therapies for ATTR amyloidosis

Get Full Report Here: 2023-2028 Global and Regional Tafamidis Meglumine Industry Status and Prospects Professional Market – View in Detailed Research Report

The companies listed above are not only providing critical treatments—they’re advancing the therapeutic landscape for patients with rare systemic amyloidosis diseases.